Skip to main content
2023 ACVIM Forum Main banner
Final Program


2023 Event Program
Icon Legend
This session is not on your agenda.
This session is on your agenda. Click again to remove it.
Presentation Icons
ACVIM Resident Research Award Eligible
ACVIM Resident Research Award Eligible
Additional Fees May Be Required
Additional Fees May Be Required
By Invite Only
By Invite Only
Capturing for On Demand
Capturing for On Demand
Cardiology Research Abstract Award Eligible
Cardiology Research Abstract Award Eligible
ERC Approved Lecture for ACVIM Residency
ERC Approved Lecture for ACVIM Residency
ePoster
ePoster
Livestream
Livestream
One Health
One Health
Pre-Registration Required
Pre-Registration Required
RACE-Approved
RACE-Approved
Research Abstract
Research Abstract
Specialty Symposium
Specialty Symposium
State-of-the-Art (SOTA) Presentation
State-of-the-Art (SOTA) Presentation
Veterinary Technician
Veterinary Technician
Back
Evaluation ViewAttendees 7

Small Animal Internal Medicine

SOLD OUT: Lunch with the Experts: Update on Unlicensed Antiviral Therapies for FIP

Thursday, June 15, 2023
12:25 PM – 1:30 PM ET
Location: Marriott, Grand Ballroom, Salon L
CE: 1
Additional Fees May Be Required ERC Approved Lecture for ACVIM Residency One Health Pre-Registration Required
Various unlicensed compounds (including GS-441524, EIDD-2801/molnupiravir, GC376, remdesivir, and others) are being successfully used to treat and cure FIP around the globe. As these drugs are mostly obtained on the black market in North America, this is largely occurring in clients' homes with little veterinary oversight. This session will discuss recent research related to this phenomenon, including prospective survey data of patients from diagnosis through observation, a brief comparison of efficacy among the various forms available, treatment statistics in retrovirus positive patients, long-term prognosis in our original study-set of cats ~3 years post-treatment, and compound analysis (content, purity, pH) of the more commonly utilized unlicensed formulations.

Learning Objectives:

  • Define the extent of unlicensed drug use (including newer options other than GS-441524) for treating FIP, and describe the treatment methodology being used by lay owners and social media website administrators.
  • Discuss short and long-term treatment outcomes based on prospectively collected data following cats treated for FIP with unlicensed therapy, including for subgroups of different clinical forms of FIP and cats with comorbidities.
  • Compare the drug content, concentration, purity, pH, and batch variability of various unlicensed formulation of antiviral compounds sold for the treatment of FIP.